- Stocks
- Healthcare
- NYSE: ABBV

Price (delayed)

$94.68

Market cap

$167.09B

P/E Ratio

20.06

Dividend/share

$4.61

EPS

$4.72

Enterprise value

$248.51B

ABBV's revenue is up by 11% year-on-year and by 6% since the previous quarter

ABBV's P/E is 6% below its 5-year quarterly average of 21.4 and 4.9% below its last 4 quarters average of 21.1

The company's net income has surged by 69% YoY but it fell by 18% QoQ

The EPS has soared by 68% YoY but it has contracted by 17% from the previous quarter

The debt has surged by 135% year-on-year and by 30% since the previous quarter

The quick ratio has plunged by 80% from the previous quarter and by 9% YoY

What are the main financial stats of ABBV

Market
Valuations
Earnings

Shares outstanding

1.76B

Market cap

$167.09B

Enterprise value

$248.51B

Price to earnings (P/E)

20.06

Price to book (P/B)

9.51

Price to sales (P/S)

4.3

EV/EBIT

26.44

EV/EBITDA

19.84

EV/Sales

6.86

Revenue

$36.23B

EBIT

$9.4B

EBITDA

$12.52B

Free cash flow

$14.12B

Per share
Balance sheet
Liquidity

EPS

$4.72

Free cash flow per share

$8.57

Book value per share

$9.96

Revenue per share

$22

TBVPS

$18.46

Total assets

$149.53B

Total liabilities

$134.8B

Debt

$87.43B

Equity

$14.71B

Working capital

-$3.39B

Debt to equity

5.94

Current ratio

0.86

Quick ratio

0.58

Net debt/EBITDA

6.5

Margins
Efficiency
Dividend

EBITDA margin

34.6%

Gross margin

73.6%

Net margin

19.2%

Operating margin

30.2%

Return on assets

7.1%

Return on equity

N/A

Return on invested capital

14.7%

Return on capital employed

7.5%

Return on sales

25.9%

Dividend yield

4.87%

DPS

$4.61

Payout ratio

97.7%

How has the AbbVie stock price performed over time

How have AbbVie's revenue and profit performed over time

Revenue

$36.23B

Gross profit

$26.65B

Operating income

$10.93B

Net income

$6.96B

Gross margin

73.6%

Net margin

19.2%

The company's net income has surged by 69% YoY but it fell by 18% QoQ

The operating income has soared by 53% YoY but it has contracted by 20% from the previous quarter

The net margin has surged by 52% year-on-year but it has declined by 23% since the previous quarter

The operating margin rose by 39% year-on-year but it has declined by 24% since the previous quarter

What is AbbVie stock price valuation

P/E

20.06

P/B

9.51

P/S

4.3

EV/EBIT

26.44

EV/EBITDA

19.84

EV/Sales

6.86

The EPS has soared by 68% YoY but it has contracted by 17% from the previous quarter

ABBV's P/E is 6% below its 5-year quarterly average of 21.4 and 4.9% below its last 4 quarters average of 21.1

ABBV's P/S is 13% above its last 4 quarters average of 3.8 and 2.4% above its 5-year quarterly average of 4.2

ABBV's revenue is up by 11% year-on-year and by 6% since the previous quarter

How efficient is AbbVie business performance

The ROS has soared by 69% YoY but it has contracted by 17% from the previous quarter

AbbVie's return on assets has decreased by 38% QoQ but it has increased by 2.9% YoY

AbbVie's ROIC has decreased by 29% from the previous quarter but it has increased by 13% YoY

What is ABBV's dividend history

DPS

$4.61

Dividend yield

4.87%

Payout ratio

97.7%

Recent dividends

How did AbbVie financials performed over time

AbbVie's total assets is 11% higher than its total liabilities

AbbVie's total assets has surged by 162% YoY and by 64% QoQ

The total liabilities has surged by 105% year-on-year and by 37% since the previous quarter

The debt has surged by 135% year-on-year and by 30% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.